Dana M Chase, Linda Kalilani, Maureen A Cooney, Zsofia Kiss, Amanda K Golembesky, Monica Kobayashi, Megha Dayma, Elif Coskuncay, Jeanne M Schilder
{"title":"美国晚期卵巢癌患者2020年后一线维持治疗模式的现实世界","authors":"Dana M Chase, Linda Kalilani, Maureen A Cooney, Zsofia Kiss, Amanda K Golembesky, Monica Kobayashi, Megha Dayma, Elif Coskuncay, Jeanne M Schilder","doi":"10.1080/14796694.2025.2526273","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims: </strong>To describe first-line maintenance (1LM) treatment patterns since 1 January 2020, for real-world patients with newly diagnosed advanced ovarian cancer (aOC).</p><p><strong>Patients & methods: </strong>This retrospective study used a US-nationwide electronic health record-derived deidentified database. Eligible patients were aged ≥ 18 years with stage III/IV epithelial OC and initiated first-line platinum-based chemotherapy±bevacizumab (index; 01Jan2020-28Feb2023). Baseline characteristics and 1LM treatment patterns were summarized overall and by <i>BRCA</i> status.</p><p><strong>Results: </strong>Among 599 eligible patients (median [interquartile range] age, 67 [59-74] years; 59.8% White; 50.3% stage III disease), 15.5% had <i>BRCA</i>-mutated (<i>BRCA</i>m), 72.3% <i>BRCA</i> wild-type (<i>BRCA</i>wt), and 12.2% unknown <i>BRCA</i> status. Overall, 289 patients (48.2%) received 1LM therapy (poly(ADP-ribose) polymerase inhibitor [PARPi] monotherapy, 23.4%; bevacizumab monotherapy, 14.7%; bevacizumab+PARPi, 7.8%; other therapies, 2.3%). PARPi monotherapy was most common among patients with <i>BRCA</i>m (47.3%) versus <i>BRCA</i>wt (21.7%) or <i>BRCA-</i>unknown (2.7%) status. The same was true for 1LM bevacizumab+PARPi (<i>BRCA</i>m, 16.1%; <i>BRCA</i>wt, 7.4%; <i>BRCA-</i>unknown, 0%). Bevacizumab monotherapy was most common among patients with <i>BRCA</i>wt (18.7%) versus <i>BRCA</i>m (3.2%) or <i>BRCA-</i>unknown (5.5%) status.</p><p><strong>Conclusions: </strong>Fewer than half of included patients with aOC received 1LM treatment in the real-world setting. More work is needed to understand reasons underlying real-world 1LM treatment choice for patients with aOC.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2495-2503"},"PeriodicalIF":2.6000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12330229/pdf/","citationCount":"0","resultStr":"{\"title\":\"Real-world post-2020 first-line maintenance treatment patterns in patients with advanced ovarian cancer in the US.\",\"authors\":\"Dana M Chase, Linda Kalilani, Maureen A Cooney, Zsofia Kiss, Amanda K Golembesky, Monica Kobayashi, Megha Dayma, Elif Coskuncay, Jeanne M Schilder\",\"doi\":\"10.1080/14796694.2025.2526273\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aims: </strong>To describe first-line maintenance (1LM) treatment patterns since 1 January 2020, for real-world patients with newly diagnosed advanced ovarian cancer (aOC).</p><p><strong>Patients & methods: </strong>This retrospective study used a US-nationwide electronic health record-derived deidentified database. Eligible patients were aged ≥ 18 years with stage III/IV epithelial OC and initiated first-line platinum-based chemotherapy±bevacizumab (index; 01Jan2020-28Feb2023). Baseline characteristics and 1LM treatment patterns were summarized overall and by <i>BRCA</i> status.</p><p><strong>Results: </strong>Among 599 eligible patients (median [interquartile range] age, 67 [59-74] years; 59.8% White; 50.3% stage III disease), 15.5% had <i>BRCA</i>-mutated (<i>BRCA</i>m), 72.3% <i>BRCA</i> wild-type (<i>BRCA</i>wt), and 12.2% unknown <i>BRCA</i> status. Overall, 289 patients (48.2%) received 1LM therapy (poly(ADP-ribose) polymerase inhibitor [PARPi] monotherapy, 23.4%; bevacizumab monotherapy, 14.7%; bevacizumab+PARPi, 7.8%; other therapies, 2.3%). PARPi monotherapy was most common among patients with <i>BRCA</i>m (47.3%) versus <i>BRCA</i>wt (21.7%) or <i>BRCA-</i>unknown (2.7%) status. The same was true for 1LM bevacizumab+PARPi (<i>BRCA</i>m, 16.1%; <i>BRCA</i>wt, 7.4%; <i>BRCA-</i>unknown, 0%). Bevacizumab monotherapy was most common among patients with <i>BRCA</i>wt (18.7%) versus <i>BRCA</i>m (3.2%) or <i>BRCA-</i>unknown (5.5%) status.</p><p><strong>Conclusions: </strong>Fewer than half of included patients with aOC received 1LM treatment in the real-world setting. More work is needed to understand reasons underlying real-world 1LM treatment choice for patients with aOC.</p>\",\"PeriodicalId\":12672,\"journal\":{\"name\":\"Future oncology\",\"volume\":\" \",\"pages\":\"2495-2503\"},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2025-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12330229/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Future oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/14796694.2025.2526273\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/7/14 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14796694.2025.2526273","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/14 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
Real-world post-2020 first-line maintenance treatment patterns in patients with advanced ovarian cancer in the US.
Aims: To describe first-line maintenance (1LM) treatment patterns since 1 January 2020, for real-world patients with newly diagnosed advanced ovarian cancer (aOC).
Patients & methods: This retrospective study used a US-nationwide electronic health record-derived deidentified database. Eligible patients were aged ≥ 18 years with stage III/IV epithelial OC and initiated first-line platinum-based chemotherapy±bevacizumab (index; 01Jan2020-28Feb2023). Baseline characteristics and 1LM treatment patterns were summarized overall and by BRCA status.
Results: Among 599 eligible patients (median [interquartile range] age, 67 [59-74] years; 59.8% White; 50.3% stage III disease), 15.5% had BRCA-mutated (BRCAm), 72.3% BRCA wild-type (BRCAwt), and 12.2% unknown BRCA status. Overall, 289 patients (48.2%) received 1LM therapy (poly(ADP-ribose) polymerase inhibitor [PARPi] monotherapy, 23.4%; bevacizumab monotherapy, 14.7%; bevacizumab+PARPi, 7.8%; other therapies, 2.3%). PARPi monotherapy was most common among patients with BRCAm (47.3%) versus BRCAwt (21.7%) or BRCA-unknown (2.7%) status. The same was true for 1LM bevacizumab+PARPi (BRCAm, 16.1%; BRCAwt, 7.4%; BRCA-unknown, 0%). Bevacizumab monotherapy was most common among patients with BRCAwt (18.7%) versus BRCAm (3.2%) or BRCA-unknown (5.5%) status.
Conclusions: Fewer than half of included patients with aOC received 1LM treatment in the real-world setting. More work is needed to understand reasons underlying real-world 1LM treatment choice for patients with aOC.
期刊介绍：
Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community.
The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
